Participated · Series D · May 2026

Full-Life is a clinical-stage radiotherapeutics company with a discovery platform called UniRDC™ that has produced multiple pipeline programs. Its lead and pipeline assets include potential best-in-class [225Ac]-FL-020 for prostate cancer and potential first-in-class [225Ac]-FL-261 for multiple solid tumor indications. The company plans to have three differentiated clinical-stage programs by the end of 2026 and to bring GMP-grade 225Ac manufacturing online at its Belgium facility to control isotope supply and production. Financially, Full-Life announced a US$150 million financing in 2026 (approximately US$110 million Series D equity and US$40 million debt) and has raised nearly US$350 million since founding in 2021. The company operates globally with locations referenced in Suzhou, China and Gembloux, Belgium.

Led · Seed · Jun 2024

Tesseract Medicines develops targeted therapeutics described in the article as "covalent induced conjugate" drugs designed to deliver cytotoxic payloads precisely to cancer-relevant intracellular proteins. The company is primarily engaged in R&D of these targeted delivery drugs. Its platform aims to achieve selective intracellular targeting of cancer-specific proteins to improve therapeutic index. The article reports the company completed a financing event, indicating early-stage commercial funding activity to support development. No revenue or user metrics are provided in the article. The report does not state a founding year or headquarters location. Public disclosure about further clinical or commercial plans beyond R&D was not included in the article.

Led · Seed · Dec 2023

Perpetual Medicines has built an integrated platform that combines physics-based computational methods, next-generation AI, and advanced synthetic chemistry to explore vast peptide chemical space and predict binding and drug-like properties. The platform virtually iterates through millions of peptide sequences and integrates computational predictions with experimental data to discover and optimize product candidates. With the new financing the company plans to advance its lead program to the clinical stage and continue building a preclinical portfolio across oncology, autoimmunity, and metabolic diseases. Perpetual positions peptide therapeutics as a rapidly growing sector that can address targets between small molecules and antibodies, enabling access to previously undruggable biology. The company has operations in Shanghai and Boston and has assembled a senior management team with more than 120 years of combined drug discovery experience and involvement in over ten marketed peptide therapeutics. It closed an $8 million seed financing led by Chengwei Capital to advance its platform and programs.

Participated · Series A · Nov 2023

Jushu Bio builds an engineering platform for microbial and mammalian chassis cells using whole‑genome editing, ultra‑high‑throughput droplet microfluidics, genome‑scale metabolic network models and deep learning. The company develops and industrializes products across healthcare, bio‑based chemicals and materials, bio‑agriculture and future foods, and aims to deliver a next‑generation CHO+microbial high‑throughput protein production platform. It operates its own R&D and production lines and has established technology and industrial collaborations with multiple listed companies and research institutions. Jushu Bio plans to focus on application development and scale production to drive industrial adoption of synthetic biology. Financially, the company has just completed a Pre‑A equity financing of over ¥100 million RMB. No revenue or user metrics were disclosed in the article.

Led · Series A · Jun 2022

Raythink develops AR head-up display (HUD) hardware and software including OpticalCore® imaging modules and the AR Generator® SDK, focused on automotive and rail smart-driving and cockpit applications. The company highlights proprietary optics, PGU, AR Generator SDK, algorithms, structure and hardware enabling continuous-zoom AR HUD effects and an LBS light-source approach that is in final vehicle certification. Raythink has begun multiple series production deliveries in the passenger-car market and is collaborating with China Railway Signal & Communication on a high-speed-rail intelligent-assist driving system now in system testing. The firm has roughly 200 engineers across international R&D centers and has established a wholly owned subsidiary and an intelligent manufacturing base in Suzhou High-Speed Rail New City, with planned capacity expected to exceed 500,000 units per year. Raythink holds IATF16949 certification, is advancing AEC-Q100 qualification for its LBS light-source module, and has its OpticalCore® module entering production-line buildout. The company is expanding overseas engagement, including exhibiting at the Tokyo Motor Show and pursuing projects with Japanese OEMs and Tier-1 partners. Founded in 2019 and headquartered in Shenzhen, Raythink develops AR HUD hardware, software and algorithms including optics, picture generation units (PGUs) and an AR Generator® SDK. The company offers three AR HUD product lines (AR HUD PRO, AR HUD, and Mini AR HUD) covering 1–3 lanes for high-, mid- and entry-level vehicles and claims automotive-grade mass production capacity. Raythink holds more than 100 invention and innovation patents across AR navigation and driver-safety systems and operates R&D centers in Changsha, Taipei and Bangalore. It recently obtained IATF16949 certification, which the company says lays the foundation for wider mass-production deployment in mainstream vehicle models. Raythink is expanding partnerships with Tier 1 suppliers and has POC projects and bids with name-brand carmakers; it is also collaborating with China Railway Signal & Communication on an assisted-driving solution for high-speed trains. The company plans to accelerate iteration of its technologies and expand headcount and production capacity to seize first-mover advantages in AR display adoption. Raythink develops in-vehicle augmented reality heads-up display (AR-HUD) technology and provides a software development kit (SDK) that integrates maps and service data with vehicle systems. The SDK interfaces with GPS, cameras, sensors, millimeter-wave radar, lidar and other ADAS sensors to enable AR-HUD functionality. Automakers can install the SDK into vehicle systems to support safe navigation, safer driving and provide crossroad reminders. Raythink aims to drive implementation of in-vehicle AR displays in rail transit and passenger car scenarios. The company intends to use recent funding to build a rail transit laboratory, pursue HUD mass production, and obtain automotive-grade certification. Founded in 2019 and led by CEO Ray Lu, Raythink is based in Shenzhen, China.